Prediction and prevention of sudden cardiac death in heart failure (ht25254

RE Lane, MR Cowie, AWC Chow

Web only references

1. Adgey AA, Devlin JE, Webb SW, *et al*. Initiation of ventricular fibrillation outside hospital in patients with acute ischaemic heart disease. *Br Heart J* 1982;**47**:55–61.

2. Tamburro P, Wilber D. Sudden death in idiopathic dilated cardiomyopathy. *Am Heart J* 1992;**124**:1035–45.

3. Middlekauff HR, Stevenson WG, Stevenson LW, *et al*. Syncope in advanced heart failure: high risk of sudden death regardless of origin of syncope. *J Am Coll Cardiol* 1993;**21**:110–6.

4. Fonarow GC, Feliciano Z, Boyle NG, *et al*. Improved survival in patients with nonischemic advanced heart failure and syncope treated with an implantable cardioverter-defibrillator. *Am J Cardiol* 2000;**85**:981–5.

5. Knight BP, Goyal R, Pelosi F, *et al*. Outcome of patients with nonischemic dilated cardiomyopathy and unexplained syncope treated with an implantable defibrillator. *J Am Coll Cardiol* 1999;**33**:1964–70.

6. Mehta D, Saksena S, Krol RB, *et al*. Device use patterns and clinical outcome of implantable cardioverter defibrillator patients with moderate and severe impairment of left ventricular function. *Pacing Clin Electrophysiol* 1993;**16**:179–85.

7. Bode-Schnurbus L, Bocker D, Block M, *et al*. QRS duration: a simple marker for predicting cardiac mortality in ICD patients with heart failure. *Heart* 2003;**89**:1157–62.

8. Aaronson KD, Schwartz JS, Chen TM, *et al*. Development and prospective validation of a clinical index to predict survival in ambulatory patients referred for cardiac transplant evaluation. *Circulation* 1997;**95**:2660–7.

9. Anastasiou-Nana MI, Nanas JN, Karagounis LA, *et al*. Relation of dispersion of QRS and QT in patients with advanced congestive heart failure to cardiac and sudden death mortality. *Am J Cardiol* 2000;**85**:1212–7.

10. Brendorp B, Elming H, Jun L, *et al*. Qt dispersion has no prognostic information for patients with advanced congestive heart failure and reduced left ventricular systolic function. *Circulation* 2001;**103**:831–5.

11. Hohnloser SH, Klingenheben T, Zabel M, *et al*. Prevalence, characteristics and prognostic value during long-term follow-up of nonsustained ventricular tachycardia after myocardial infarction in the thrombolytic era. *J Am Coll Cardiol* 1999;**33**:1895–902.

12. Doval HC, Nul DR, Grancelli HO, *et al*. Nonsustained ventricular tachycardia in severe heart failure. Independent marker of increased mortality due to sudden death. GESICA-GEMA Investigators. *Circulation* 1996;**94**:3198–203.

13. Berbari EJ, Scherlag BJ, Hope RR, *et al*. Recording from the body surface of arrhythmogenic ventricular activity during the S-T segment. *Am J Cardiol* 1978;**41**:697–702.

14. El Sherif N, Denes P, Katz R, *et al*. Definition of the best prediction criteria of the time domain signal-averaged electrocardiogram for serious arrhythmic events in the postinfarction period. The Cardiac Arrhythmia Suppression Trial/Signal-Averaged Electrocardiogram (CAST/SAECG) Substudy Investigators. *J Am Coll Cardiol* 1995;**25**:908–14.

15. Turitto G, Ahuja RK, Caref EB, *et al*. Risk stratification for arrhythmic events in patients with nonischemic dilated cardiomyopathy and nonsustained ventricular tachycardia: role of programmed ventricular stimulation and the signal-averaged electrocardiogram. *J Am Coll Cardiol* 1994;**24**:1523–8.

16. Ommen SR, Hammill SC, Bailey KR. Failure of signal-averaged electrocardiography with use of time-domain variables to predict inducible ventricular tachycardia in patients with conduction defects. *Mayo Clin Proc* 1995;**70**:132–6.

17. Hohnloser SH, Ikeda T, Bloomfield DM, *et al*. T-wave alternans negative coronary patients with low ejection and benefit from defibrillator implantation. *Lancet* 2003;**362**:125–6.

18. Kitamura H, Ohnishi Y, Okajima K, *et al*. Onset heart rate of microvolt-level T-wave alternans provides clinical and prognostic value in nonischemic dilated cardiomyopathy. *J Am Coll Cardiol* 2002;**39**:295–300.

19. Cowie MR, Jourdain P, Maisel A, *et al*. Clinical applications of B-type natriuretic peptide (BNP) testing. *Eur Heart J* 2003;**24**:1710–8.

20. Cleland JG, Coletta AP, Nikitin N, *et al*. Update of clinical trials from the American College of Cardiology 2003. EPHESUS, SPORTIF-III, ASCOT, COMPANION, UK-PACE and T-wave alternans. *Eur J Heart Fail* 2003;**5**:391–8.

21. Dargie HJ. Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial. *Lancet* 2001;**357**:1385–90.

22. Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. The Cardiac Arrhythmia

Suppression Trial (CAST) Investigators [see comments]. *N Engl J Med* 1989;**321**:406–12.

23. Haverkamp W, Martinez-Rubio A, Hief C, *et al*. Efficacy and safety of d,l-sotalol in patients with ventricular tachycardia and in survivors of cardiac arrest. *J Am Coll Cardiol* 1997;**30**:487–95.